Bronchitol available to named patients
Tuesday, 17 June, 2008
Pharmaxis (ASX: PXS) will soon be distributing its Bronchitol drug on a named patient basis through UK company IDIS.
Under the arrangement doctors can - through IDIS - prescribe Bronchitol to patients not currently undergoing clinical trials of the drug.
Patients who participate in a named patient program are warned that a drug may have unexpected side-effects, and their doctors are generally indemnified from liability as a result of this disclaimer.
The programs are generally used to allow patients with chronic illnesses access to drugs which can potentially help even in countries where the drug has not yet been cleared for sale. It is particularly used in cases where there is no satisfactory alternative available.
Bronchitol is an inhalant spray aimed at cystic fibrosis and bronchiectasis.
NSW Govt delivers foot-and-mouth vaccine to protect livestock
A biodegradable vaccine to protect livestock from foot-and-mouth disease has been developed as...
Scientists optimise delivery of mRNA to target cells
A highly versatile new method captures and attaches antibodies to the surface of mRNA-loaded...
'Anti-reward' brain network helps explain cocaine addiction
A new study identifies a specific 'anti-reward' network deep in the brain that undergoes...
